OncoSil Medical (ASX: OSL) has received an ASX “speeding ticket” following a 47.7% spike in its share price to an intra day high of $0.13 today from $0.088 on 13 August 2013.
The company said it is not aware of any unannounced information that if known could be an explanation for the recent trading in its securities.
It added that it had released the announcements that it was initiating a US FDA gap analysis on 8 August and a manufacturing alliance on 23 July.
The company also said it had increased the promotion of the company to the investment markets.
OncoSil is developing its pancreatic cancer treatment medical device OncoSil™ as an implantable device that emits radiation directly into the pancreatic tumour, and the pain conducting nerves surrounding it.
Notably, the company is seeking to register OncoSil™ as a medical device in all major markets as they have a fraction of the development cost compared to drugs and are faster to register, making for a better return on investment.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.